Dr Michael Shepard has been appointed to the Scientific Advisory Board of Hemogenyx Pharmaceuticals. Michael is a pioneer in modern cancer research. His work has led to the discovery and development of many successful cancer treatments including Herceptin/trastuzumab. In 2006, he received Harvard Medical School’s prestigious Warren Alpert Prize in recognition of contributions to the field of cancer treatment research.
